Skip to main content

COVID 19 Updates from RheumNow

Pre-exposure Prophylaxis for COVID-19 (4.22.22)

Dr. Jack Cush discusses the news and recent journal reports from last weeks RheumNow.com, and answers viewer questions from #ACA - Ask Cush Anything.

COVID-19 Vaccination Uptake and Perceptions in Rheumatic Patients

Putman et al has reported vaccine survey results from the COVID-19 Global Rheumatology Alliance (C19-GRA) in Lancet Rheumatology showing the uptake and vaccine hesitancy among people with rheumatic diseases (RMD).

Evusheld as Protective Therapy in High Risk COVID-19 Patients

A single dose of the monoclonal-antibody AZD7442 (combination of tixagevimab and cilgavimab) has been shown to be safe and effective as prophylaxis against COVID-19 infection in high risk individuals who tested positive for COVID-19. 

Male vs. Female Responders (4.15.2022)

Dr. Jack Cush reviews the news and journal Reports from the past week on RheumNow.com - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic. 

Consensus Best Practices for Virtual Care in Rheumatology

The Canadian Rheumatology Association’s (CRA) Telehealth Working Group (TWG) has developed a series of best practice statements for the virtual care in adult and pediatric rheumatology patients.

ACR Fellow Training Subcommittee Report on Pandemic Experiences

Arthritis & Rheumatology has publish an ACR Subcommittee report on how the COVID-19 pandemic affected fellows and their training. 

RheumNow Podcast – What You Do For & What You Do To the Patient (4.8.2022)

Dr. Jack Cush reviews the news and journal articles from the past week and discusses the use of fibroscan in RA, steroid hip injections in OA and famous quotes from a famous cardiologist.

FDA Authorizes 2nd Booster for Older and Immunocompromised Individuals

FDA

Today, the U.S. Food and Drug Administration authorized a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for older people and certain immunocompromised individuals.

Are Shoulder Conditions Incited by Vaccination?

A retrospective cohort study from Kaiser Permanente Southern California intramuscular vaccination given between 2016 and 2017 shows a small but significant increase in shoulder conditions, reported as an adverse event (AE) following intramuscular vaccination in the deltoid muscle. 

Consequences of TNF inhibition (3.18.2022)

This week we're going to talk about the downside of TNF inhibitors, a few interesting observations in gout, and yes, kids do get COVID. We're also going to preview what's coming in April! This and more as Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Baricitinib’s COVID-19 Efficacy in the RECOVERY Trial

Pre-print results of the RECOVERY Trial has shown that when baricitinib (BAR) is given to hospitalized severe COVID-19 patients, it results in significantly less mortality.

Tocilizumab Works Best in Non-Mechanical Ventilated COVID-19 Patients

JAMA has published a meta-analysis of 15 studies of hospitalized patients with COVID-19 treated with tocilizumab and corticosteroids, showing that a clinically meaningful mortality benefit from tocilizumab (and steroids) was best seen in those not requiring invasive mechanical ventilation (IMV).

Social

#POS1236 #EULAR2022 More data to justify safety of #COVID vaccination to our #lupus patients. A study in Italy (>450 pts) found 1/4 had side effects (mostly mild) and 4% had a flare. These side effects were more common in those on >1 DMARDS and Belimumab @RheumNow https://t.co/mNS6rQfsSq
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
1 month ago
Please see my short video on Promising Safety Outlook for Rituximab and Baricitinib in Vaccinated Patients #EULAR2022 @RheumNow https://t.co/bqzdWIzoOg

Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )

1 month ago
#COVID19 #pandemic has affected #rheumatology training Negative impact on ▶️Learning ▶️Research ▶️Mental health ▶️Physical health 👉🏽https://t.co/Irtkg8TjZtBy @kristenyoung @SuAnnYeoh1 @EBRheum @SattuiSEMD @RichardPAConway @SituationRheum @KilianMD @rheum_covid et al @RheumJnl https://t.co/wysWzE92Fm
Dr Ai Lyn Tan @DrAiLynTan ( View Tweet )
1 month ago
Yusof et al @Yuz6Yusof COVID-19 in RTX treated patients. Significant efficacy of vaccination in both overall and severe COVID rates. Vaccination decreased risk HR 0.13 (0.03-0.51). Number comorbidities and low IgG increase risk @RheumNow #EULAR2022 OP0250 https://t.co/yD1tvs1UYt https://t.co/23XTtPb8fD
Richard Conway @RichardPAConway ( View Tweet )
1 month ago
Roberto Giacomeilli from Italy explaining the mechanisms on how COVID-19 may cause rheumatic disease #EULAR2022 @RheumNow https://t.co/a2kTT7vcRx
Dr. Antoni Chan @synovialjoints ( View Tweet )
1 month ago
COVID-19 mostly mild for majority of SpA patients. Steroid use associated with more severe COVID-19 outcomes (OR 3.15). TNFi found to be protective! (OR 0.26) @RheumNow #EULAR2022 ABST#OP0254

Robert B Chao, MD @doctorRBC ( View Tweet )

1 month ago
#EULAR2022 POS0196 found 9% of post-COVID19 patients developed MSK symptoms. @RheumNow https://t.co/YFT83TjXFL
Dr. Rachel Tate @uptoTate ( View Tweet )
1 month ago
Dr Yeoh @SuAnnYeoh1 @rheum_covid Factors assoc severe COVID outcomes in IIM. Age, male, high disease activity, 2+ comorbidities, pred>7.5mg, RTX, assoc hospitalisation or death @RheumNow #EULAR2022 OP0252 https://t.co/PvCeSX8UvF https://t.co/RaISpeUNsH
Richard Conway @RichardPAConway ( View Tweet )
1 month ago
#EULAR2022 POS0199 showed marked decrease in SARS-CoV2 IgG ab 6 months after initial two dose vaccines. @RheumNow https://t.co/lZdWQUqFvf
Dr. Rachel Tate @uptoTate ( View Tweet )
1 month ago
#OP0252 #EULAR2022 Dr Yeoh presented data from Global Rheum Alliance of >300 pts with myositis. 13% died. Usual suspects re: Factors assoc with poor #COVID outcome: age, active disease,on steroid,male and RTX exposure. Be interesting to see longer followup post-booster @RheumNow https://t.co/F7qaee5ADK
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
1 month ago
×